Large holder update, amended
Open the filing on sec.gov
BridgeBio Pharma, Inc. (BBIO)
Nasdaq: BBIO · Pharmaceutical Preparations · Palo Alto, CA · filing with the SEC since 2018
The companyfiscal 2025, as filed
Revenue$502M+126.3%
Net income-$733M-34.9%
Earnings per share$-3.78-31.3%
Operating cash flow-$446M+14.4%
Cash$570M-16.3%
Debt$2.01B+2038.2%
Shareholders’ equity-$2.09B-42.1%
Shares, diluted191.5M+2.9%
Return on equityn/a
The recordfrom its filings
Filings in 2026111
Newest filingNov 12 · SCHEDULE 13G/A
Annual reportFeb 24, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$105M
Insider buys, 12 months$0.00
Patents granted23
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $946MNet income -$578MCash from operations -$369Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.